The importance of genotoxicity tests in new drug development process<p>Genotoksisite testlerinin yeni ilaç geliştirme sürecindeki önemi
Keywords:
Preclinical drug evaluation, genotoxicity tests, DNA damage, international guidelines, Preklinik ilaç değerlendirmesi, genotoksisite testleri, DNA hasarı, uluslararası kılavuzlarAbstract
In the preclinic investigation period at the beginning of the drug development process, it is an obligation to subject candidate drugs to genotoxicty investigations. Genotoxicty data of drugs that are developed with these tests are demanded as a part of the security evaluation process by regulatory authorities in various countries. The demand of these laboring and costly data by regulatory authorities of various countries in different standards prevents potential candidate drugs from being marketed, interrupts the drug development process and causes unnecessary utilization of experimental materials in researches. Therefore, nowadays, it is generally accepted that the researches aimed at achieving these data are implemented with standardized approaches in the guidelines of international harmonisation organizations such as ICH (International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) and OECD (Organisation for Economic Cooperation and Development). In this review, it is aimed to provide current information about the various genotoxicity tests which are used commonly in the drug development process, in accordance with ICH, OECD guidelines and literature.
Extended English summary is in the end of Full Text PDF (TURKISH) file.Özet
İlaç geliştirme sürecinin başlangıcındaki preklinik araştırma döneminde, aday ilaçların genotoksisite testlerinden geçirilmesi bir zorunluluktur. Bu testlerle elde edilen genotoksisite verileri, çeşitli ülkelerdeki düzenleyici otoriteler tarafından güvenlilik değerlendirme sürecinin bir parçası olarak istenmektedir. Elde edilmesi oldukça zahmetli ve maliyetli olan bu bilgilerin, farklı ülkelerin düzenleyici otoriteleri tarafından değişik standartlarda istenmesi, potansiyel ilaç adaylarının pazarlamasını engellemekte, ilaç geliştirme sürecini kesintiye uğratmakta ve araştırmalarda gereksiz yere deney materyali kullanımına neden olmaktadır. Bu bakımdan, günümüzde bu bilgileri elde etmeyi amaçlayan araştırmaların, ICH (İnsanda Kullanılan İlaçların Ruhsatlandırılması İçin Teknik Gerekliliklerin Uyumlandırılması Uluslararası Birliği) ve OECD (Ekonomik Kalkınma ve İşbirliği Örgütü) gibi uluslararası harmonizasyon örgütlerinin kılavuzlarında standardize edilen yaklaşımlarla uygulanması genel kabul görmektedir. Bu derlemede, ilaç geliştirme sürecinde kullanılan genotoksisite testlerine ilişkin, ICH, OECD kılavuzları ve literatür ışığında güncel bilgiler verilmesi amaçlanmıştır.
Downloads
Metrics
References
Albertini, R. J. (2001). HPRT mutations in humans: biomarkers for mechanistic studies. Mutation Research/Reviews in Mutation Research, 489(1), 1-16.
Albertini, R. J. (2004). Mechanistic insights from biomarker studies: somatic mutations and rodent/human comparisons following exposure to a potential carcinogen. IARC Scientific Publications, 157, 153-177.
Arodola OA, Soliman MES. (2017). Quantum mechanics implementation in drug-design work-flows: does it really help? Drug Design, Development and Therapy, 11, 2551-2564.
Au, W. W. (2007). Usefulness of biomarkers in population studies: from exposure to susceptibi-lity and to prediction of cancer. International Journal of Hygiene Environmental Health, 210(3), 239-246.
Bajpayee, M., Pandey A. K., Parmar, D., Dhawan, A. (2005). Current status of short-term tests for evaluation of genotoxicity, mutagenicity and carcinogenicity of environmental chemicals and NCEs. Toxicology Mechanisms and Methods, 15(3), 155-180.
Bonassi, S., Abbondandolo, A., Camurri, L., Dal Prá, L., De Ferrari, M., Degrassi, F., .. & Sbrana, I. (1995). Are chromosome aberrations in circulating lymphocytes predictive of futurecancer onset in humans? Preliminary results of an Italian cohort study. Cancer genetics and cytogenetics, 79(2), 133-135.
Bonassi, S., Hagmar, L., Strömberg, U., Montagud, A. H., Tinnerberg, H., Forni, A., .. & Knudsen, L. E. (2000). Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Research, 60(6), 1619-1625.
Bonassi, S., Znaor, A., Ceppi, M., Lando, C., Chang, W. P., Holland, N., ... & Bigatti, M. P. 2007). An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis, 28(3), 625-631.
Bostancı, Ş. Ö. (2014). Bazı benzotiyazol türevi bileşiklerin mutejenik potansiyellerinin ames test sistemi ile belirlenmesi, H.Ü. Fen Bilimleri Enstitüsü, Yüksek Lisans Tezi.
Brambilla, G., Mattioli, F., Rbiano, L., Martelli, A. (2012). Update carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals. Mutation Research. 750(1), 1-51.
Brummelan, P. V. (2007). İlaç geliştirilmesi. Türk Eczacılar Birliği Yayını. İlaç yararları ve riskleri, farmakolojiye giriş. 113-127 (Cited: 23.05.2018, Available at: http://e- kutuphane.teb.org. tr/pdf/raporlar/ilac_risk/11.pdf).
Cardoso, R. S., Takahashi‐Hyodo, S., Peitl, P., Ghilardi‐Neto, T., & Sakamoto‐Hojo, E. T. (2001) Evaluation of chromosomal aberrations, micronuclei, and sister chromatid exchanges in hospital workers chronically exposed to ionizing radiation. Teratogenesis, carcinogenesis and mutagenesis, 21(6), 431-439.
Ciociola, A. A., Cohen, L. B., Kulkarni, P., Kefalas, C., Buchman, A., Burke, C., ... & Fass, R. (2014). How drugs are developed and approved by the FDA: current process and future directions. The American journal of gastroenterology, 109(5), 620.
Clements, J. (2000). The mouse lymphoma assay. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 455(1), 97-110.
Dabrowska, A., Thaul, S. (2018). How FDA approves drugs and regulates their safety and effecti- veness. Congressional Research Service Report. (Cited: 15.07.2018 Available at: file:///C:/Users/LENOVO-PC/Desktop/Dabrowska%20A%20Thaul%20S%202018.pdf)
Demircigil, G. C., Emerce, E., & Ulutas, O. K. (2009). Genotoxicity tests from biomarker studies to the regulations: National perspective. FABAD Journal of Pharmaceutical Sciences, 34(4), 217.
Dikilitaş, M., Koçyiğit, A. (2010). Canlılarda tek hücre jel elektroforez yöntemi ile DNA hasar analizi (teknik not): comet analiz yöntemi. Harran Üniversitesi Ziraat Fakültesi Dergisi, 14(2), 77- 89.
Doğan, T. S., Durusoy, M., Gökçe, M., Öztürk, K. (2014). Genotoxicity of potent antiviral 1-[(2-aminophenyl)thio]- 1-phenyl-2-nitrobutane derivatives designed as drug agents. Turkish Journal of Biochemistry, 39(3), 328–335.
Fenech, M., Holland, N., Chang, W. P., Zeiger, E., & Bonassi, S. (1999). The human micronucle-us project—an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutation Research/Fundamental and Molecular Mecha-nisms of Mutagenesis, 428(1), 271-283.
Fidan, A. F. (2008). DNA hasar tespitinde tek hücre jel elektroforezi. AKÜ-Fen Bilimleri Dergisi, 8(1), 41-52.
Ginzkey, C., Steussloff, G., Koehler, C., Burghartz, M., Scherzed, A., Hackenberg, S., ... & Kleinsasser, N. H. (2014). Nicotine derived genotoxic effects in human primary parotid gland cells as assessed in vitro by comet assay, cytokinesis-block micronucleus test and chromosome aberrations test. Toxicology in vitro, 28(5), 838-846.
Hagmar, L., Bonassi, S., Strömberg, U., Brøgger, A., Knudsen, L. E., Norppa, H., & Reuterwall, C. (1998). Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer research 58(18), 4117-4121.
Hagmar, L., Brøgger, A., Hansteen, I. L., Heim, S., Högstedt, B., Knudsen, L., ... & Reuterwall, C. (1994). Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer research, 54(11), 2919-2922.
Hartmann, A., Speit, G. (2009). Comet Assay – Protocols and Testing Strategies Chapter 15. In: The Comet Assay in Toxicology. Eds: Dhawan A, Anderson D, The Royal Society of Chemistry Publishing, UK.
ICH, (2011). ICH harmonised tripartite guideline, Guidance on genotoxicity tetsing and data interpretetation for pharmaceuticals intended for human use. S2(R1), Current step 4 version.
İskit, A. B. (2006). Bir ilaç yaratmak. Klinik (ilaç) araştırma dönemleri. İKU Dergisi, 13, 10-13.
Jena, G. B., Kaul, C. L., & Ramarao, P. (2002). Genotoxicity testing, a regulatory requirement for drug discovery and development: impact of ICH guidelines. Indian journal of pharmacology, 34(2), 86-99.
Kassie, F., Parzefall, W., & Knasmüller, S. (2000). Single cell gel electrophoresis assay: a new technique for human biomonitoring studies. Mutation Research/Reviews in Mutation Research, 463(1), 13-31.
Kılıç, A. (2005). Bitkisel kaynaklı bazı uçucu yağ ve monoterpenlerin olası genotoksik etkilerinin araştırılması. A.Ü. Fen Bilimleri Enstitüsü, Yüksek Lisans Tezi.
Kirsch-Volders, M. (1997). Towards a validation of the micronucleus test. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 392(1), 1-4.
McArt, D. G., McKerr, G., Saetzler, K., Howard, C. V., Downes, C. S., & Wasson, G. R. (2010). Comet sensitivity in assessing DNA damage and repair in different cell cycle stages. Mutagenesis, 25(3), 299-303.
Moore, M. M., Honma, M., Clements, J., Bolcsfoldi, G., Cifone, M., Delongchamp, R., ... & Kirchner, S. (2003). Mouse lymphoma thymidine kinase gene mutation assay: International Workshop on Genotoxicity Tests Workgroup report—Plymouth, UK 2002. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 540(2), 127-140.
Nersesyan, A., Kundi, M., Fenech, M., Bolognesi, C., Misik, M., Wultsch, G., ... & Knasmueller, S. (2014). Micronucleus assay with urine derived cells (UDC): a review of its application in human studies investigating genotoxin exposure and bladder cancer risk. Mutation Research/Reviews in Mutation Research, 762, 37-51.
Norppa, H., Bonassi, S., Hansteen, I. L., Hagmar, L., Strömberg, U., Rössner, P., ... & Cebulska-Wasilewska, A. (2006). Chromosomal aberrations and SCEs as biomarkers of cancer riskMutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 600(1), 37-45.
OECD TG 490. Guideline for the testing of chemicals, in vitro mammalian cell gen mutation tests using the thymidine kinase gene. (Cited: 23.05.2018 Available at: http://dx.doi.org/10.1787/9789264242241-en)
OECD TG 476. In vitro mammalian cell gen mutation tests using the Hprt and Xprt genes,. Guideline for the testing of chemicals. (Cited: 23.05.2018 Available at: http//dx.doi/org/10.1787/9789264071322-en)
OECD TG 478. Rodent dominant lethal assay. Guideline for the testing of chemicals. (Cited: 23.05.2018 Available at: http://dx.doi.org/10.1787/9789264243118-en)
OECD TG 486. Unscheduled DNA synthesis assay. Guideline for the testing of chemicals. (Cited: 23.05.2018 Available at: http://dx.doi.org/10.1787/9789264071520-en)
OECD Genetic Toxicology Guidance Document: Second Commenting Round. (2015). (Cited: 23.05.2018) Available at: http://dx.doi.org/10.1787/9789264071520-en
Oguz, S., Omurtag, G. Z., Arıcıoglu, F., Sardas, S. (2013). Mutajenik-karsinojenik etkinin ames testi ile araştırılması. Marmara Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 3(2), 75-82.
Parry, J. M., & Kirsch-Volders, M. (2010). Special issue on in vitro MN trial. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 702(2), 132-134.
Preston, R. J., Skare, J. A., & Aardema, M. J. (2009). A review of biomonitoring studies measur-ing genotoxicity in humans exposed to hair dyes. Mutagenesis, 25(1), 17-23.
Rojas, E., Lopez, M. C., & Valverde, M. (1999). Single cell gel electrophoresis assay: methodology and applications. Journal of Chromatography B: Biomedical Sciences and Applications, 722(1-2), 225-254.
Santovito, A., Cervella, P., & Delpero, M. (2014). Increased frequency of chromosomal aberrati-ions and sister chromatid exchanges in peripheral lymphocytes of radiology technicianschronically exposed to low levels of ionizing radiations. Environmental toxicology and pharma-cology, 37(1), 396-403.
Sukumaran, S., & Grant, A. (2013). Differential responses of sexual and asexual artemia to geno-toxicity by a reference mutagen: Is the comet assay a reliable predictor of population level responses?. Ecotoxicology and environmental safety, 91, 110-116
Şekeroğlu, Z. A, Şekeroğlu, V. (2011a). Genetik toksisite testleri. TÜBAV Bilim Dergisi, 4(3), 221-229.
Şekeroğlu, V., Şekeroğlu, Z. A. (2011b) Genetik hasarın belirlenmesinde mikronukleus testi. Türk Hijyen ve Deneysel Biyoloji Dergisi, 2011; 68(4): 241-252.
Şen, S. Karbonik anhidraz inhibitörü metilenaminobenzen sülfonamit türevlerinin genotoksik profillerinin belirlenmesi. SAÜ Fen Bilimleri Enstitüsü, Doktora Tezi. 2018.
Tarhan, G. H. (2006). Antidepresan olarak kullanılan Paxil ve Prozac ilaçlarının insan lenfosit kültürlerindeki genotoksik etkileri. G.Ü. Fen Bilimleri Enstitüsü, Yüksek Lisans Tezi, 2006.
Thybaud, V., Delrue, N., Douglas, G. R., Lorge, E., Lovell, D. P., Moore, M. M., ... & Singer, T. (2014). Revision of Oecd guidelines for genotoxicity: current status and next steps. Mutagenesis, 29(6), 517.
Topaloğlu, H. (2014). International conference on harmonisation (ICH) nedir? Ne değildir? İKU Dergisi, 6, 7-11.
Williams, C. T. (2016). Food and Drug Administration Drug Approval Process: A History and Overview. Nursing Clinics of North America, 51(1), 1-11.
Yırtıcı, Ü. (2007). Tartrazinin Cyprinus carpio’daki genotoksik etkisinin mikronukleus yöntemi ile araştırılması. ERÜ. Fen Bilimleri Enstitüsü, Yüksek Lisans Tezi.
Yüzbaşıoğlu, D., Zengin, N., Ünal, F. (2014). Gıda koruyucuları ve genotoksisite testleri. GIDA, 39(3), 179-186.
Yüzbaşıoğlu, D., Yılmaz, E.A., Ünal, F. (2016) Antidepresan ilaçlar ve genotoksisite. TÜBAV Bilim Dergisi, 9(1), 17-28.
Zemanova, Z., Michalova, K., Buryova, H., Brezinova, J., Kostylkova, K., Bystricka, D., ... & Ransdorfova, S. (2014). Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosis. Leukemia research, 38(5), 537-544.
Downloads
Published
How to Cite
Issue
Section
License
Authors can retain copyright, while granting the journal right of first publication. Alternatively, authors can transfer copyright to the journal, which then permits authors non-commercial use of the work, including the right to place it in an open access archive. In addition, Creative Commons can be consulted for flexible copyright licenses.
©1999 Creative Commons Attribution-ShareAlike 4.0 International License.
